HVA vs IA/DA or VA in the Treatment of ND HR-AML
The Efficacy and Safety of Homoharringtonine Combined With Venetoclax and Azacitidine Versus Standard Chemotherapy or VA in the Treatment of Acute Myeloid Leukemia With High-risk, a Multicenter, Prospective, Randomized Study
Sponsor: Affiliated Hospital of Guangdong Medical University
Listed as NCT06810791, this PHASE3 trial focuses on Newly Diagnosed Acute Myeloid Leukemia With High Risk and remains actively recruiting participants. Sponsored by Affiliated Hospital of Guangdong Medical University, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
2 versions recorded-
Jun 2025 — Present [monthly]
Recruiting PHASE3
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE3
First recorded
Jan 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Affiliated Hospital of Guangdong Medical University
- Dongguan People's Hospital
- First Affiliated Hospital of Gannan Medical University
- First Affiliated Hospital of Guangxi Medical University
- First People's Hospital of Chenzhou
- First People's Hospital of Foshan
- Ganzhou City People's Hospital
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Guangdong Second Provincial General Hospital
- Guangzhou First People's Hospital
- Huizhou Municipal Central Hospital
- Hunan Provincial People's Hospital
- Jiangmen Central Hospital
- Nanfang Hospital, Southern Medical University
- People's Hospital of Guangxi Zhuang Autonomous Region
- Shenzhen Hospital of Southern Medical University
- Shenzhen Second People's Hospital
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
For direct contact, visit the study record on ClinicalTrials.gov .